Authors

Latest:

Dr. Jain on Efficacy With Maintenance Avelumab Plus BSC in Metastatic Urothelial Cancer

Rohit Jain, MD, MPH, discusses the data from the phase 3 JAVELIN Bladder 100 trial examining avelumab as maintenance therapy following response or stable disease with first-line platinum-based chemotherapy in patients with advanced or metastatic urothelial cancer.

Michael Devitt, MD

Latest:

Dr. Devitt on Utilizing PD-L1 in Biomarker-Guided Therapies in Bladder Cancer

Michael Devitt, MD, discusses utilizing PD-L1 status in biomarker-guided therapies for patients with bladder cancer.

Andrea A. Moreira, MD

Latest:

Breast Nerve Preservation and Grafting: How Surgeons Can Help Mitigate Sensation Loss

More surgeons are having in-depth conversations with their patients with breast cancer and prophylactic patients about the fact that nerves will have to be cut during their mastectomy, how that will impact sensation and quality of life, and how surgeon collaboration and breast neurotization can help restore sensation.

Rodolfo Bordoni, MD

Latest:

Dr. Bordoni on the Utility of Adjuvant Atezolizumab in the Adjuvant Setting in NSCLC

Rodolfo Bordoni, MD, discusses the utility of atezolizumab in the adjuvant setting in non–small cell lung cancer.

Saro H. Armenian, DO, MPH

Latest:

Dr Armenian on Improving Outcomes and Reducing AEs in Pediatric Oncology

Saro H. Armenian, DO, MPH, discusses treatment advancements that have helped reduce long-term adverse effects for patients in pediatric oncology.

Toon Van Gorp, MD, PhD

Toon Van Gorp, MD, PhD, a gynecologic oncologist at Universitair Ziekenhuis Leuven in Belgium.

Latest:

Dr Van Gorp on the Role of Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer

Toon Van Gorp, MD, PhD, discusses the significance of mirvetuximab soravtansine as treatment for FRα-positive, platinum-resistant ovarian cancer.

Kara M. Schenk, MD

Latest:

Dr. Schenk on the Effect of Nivolumab Plus Relatlimab in Basal Cell Carcinoma

Kara M. Schenk, MD, discusses the effect of nivolumab plus relatlimab in advanced basal cell carcinoma.

Howard Colman, MD, PhD

Howard Colman, MD, PhD, is the Jan M. Huntsman Presidential Professor in the Department of Neurosurgery, member of the Brain Tumor Research Team, and leader of the Center for Neurologic Cancers at Huntsman Cancer Institute, of the University of Utah.

Latest:

Dr Colman on Outcomes With Eflornithine in Grade 3 Anaplastic Astrocytoma

Howard Colman, MD, PhD, discusses the STELLAR trial of eflornithine plus lomustine vs lomustine alone in recurrent, IDH-mutant, anaplastic astrocytoma.

Satya (Nanu) Das, MD, MSCI

Latest:

Advice for Community Physicians Treating Patients with Neuroendocrine Tumor-Associated Carcinoid Syndrome

Drs Das, Pommier, and Zacks share their advice for community physicians treating patients who have neuroendocrine tumors with carcinoid syndrome and carcinoid heart disease.

Lance Baldo, M.D., Chief Medical Officer, Adaptive Biotechnologies Sponsored Content by Adaptive Biotechnologies

Latest:

NGS MRD Testing in Blood Cancer Is Needed Now More Than Ever

Sponsored Content by Ipsen Biopharmaceuticals, Inc.

Latest:

Finding Common Ground: Considerations for Making Treatment Decisions in R/R Follicular Lymphoma

Minsig Choi, MD, Stony Brook University Hospital

Latest:

Optimizing Treatment Strategies in R/R Hepatocellular Carcinoma

Shai Friedland, MD

Latest:

Dr. Friedland on a Multimodal Screening Blood Test to Detect CRC

Shai Friedland, MD, discusses a multimodal screening blood test for advanced adenomas in colorectal cancer.

Katherine Walsh, MD

Latest:

Preparing and Delivering a Virtual Learning Session

Strategies are important to optimize learning in the virtual environment including speaker preparation, creating a virtual learning climate, and encouraging and enhancing interaction.

Courtney R. Arn, APRN-CNP

Latest:

Advice for New Nurse Practitioners Working With Patients With Endometrial Cancer

Closing their discussion, the panel shares advice for new nurse practitioners caring for patients who have endometrial cancer.

Cristina Saura Manich, MD, PhD

Latest:

Dr Manich on the ReDiscover Study of RLY-2608 in PIK3CA-Mutant Advanced Solid Tumors

Cristina Saura Manich, MD, PhD, discusses the phase 1 ReDiscover study evaluating RLY-2608 in patients with PIK3CA-mutated advanced breast cancer and other solid tumors.

Andrew J. Wagner, MD, PhD

Latest:

Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa

Dr Wagner discusses unmet needs for patients with PEComa, ongoing research to address these gaps, and findings from the AMPECT trial.

Cara A. Mathews, MD

Latest:

Dr Mathews on Maintenance Olaparib in Ovarian Cancer

Cara A. Mathews, MD, discusses 7-year overall survival data from the phase 3 SOLO-1 trial in patients with ovarian cancer.

Srikala Sridhar, MD, MSc, FRCPC

Latest:

Dr Sridhar on the Use of Zelenectide Pevedotin in Locally Advanced or Metastatic Urothelial Cancer

Srikala Sridhar, MD, MSc, FRCPC, discusses the unique application of zelenectide pevedotin, which targets nectin-4 in locally advanced or metastatic urothelial cancer.

Pashna Munshi, MD

Latest:

Current Treatment Options for Patients with Steroid-Refractory Acute GVHD

Closing her discussion, Dr Pashna Munshi reviews recent data on the available treatment options for patients with steroid-refractory acute GVHD.